Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squam… (NCT05621707) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
China50 participantsStarted 2022-11-02
Plain-language summary
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. Locally-advanced ,medical inoperability, technical irresectability, or patient refusal to surgery;
✓. Eastern Cooperative Oncology Group (ECOG) performance status:0-2;
✓. Able to eat a semi-liquid diet;
✓. Less than 20% weight loss within 6 months;
✓. Adequate hepatic function, renal function, hematologic function and coagulation function;
✓. Documented informed consent.
Exclusion criteria
✕. Distant metastasis;
✕. Known malignancy diagnosed or require active treatment in the last 5 years, except for cancers that can be cured by surgery including cervical cancer in situ, basal or squamous cell skin cancer, breast ductal carcinoma in situ, localized prostate cancer;
✕. Prior thoracic irradiation, chemotherapy, or lobectomy
✕. Known diseases or conditions that are contraindicated for radiotherapy or surgery;